Trending

24/7 Market News – (NASDAQ:SNGX) Soligenix Inc. receives FDA clearance for phase 2 clinical trial.

Shares are up 11% in pre-market trading. on more than 1100 trades shares are at .62

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis

https://www.prnewswire.com/news-releases/soligenix-receives-fda-ind-clearance-for-phase-2-clinical-trial-of-synthetic-hypericin-in-the-treatment-of-psoriasis-301575751.html

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist